Amgen vs Broadcom: Founders, CEOs and History
Amgen was founded in 1980 by George B. Rathmann, William K. Bowes Jr. and is led by Robert A. Bradway. Broadcom was founded in 1991 by Henry Samueli, Henry Nicholas III and is led by Hock Tan.
Company facts
Founders
Amgen
George B. Rathmann
Amgen, originally incorporated as Applied Molecular Genetics, was founded in 1980 not by a single scientist, but by a calculated syndicate of venture capitalists and academics trying to commercialize the brand-new science of recombinant DNA.
William K. Bowes Jr.
William K. Bowes Jr. Was the venture capital strategist whose vision catalyzed Amgen's formation.
Broadcom
Henry Samueli
Henry Samueli co-founded Broadcom Corporation in Los Angeles in 1991 with Henry Nicholas III, his former doctoral student, and served as its chief technical officer while the company built chips for cable modems, set-top boxes, Ethernet and Wi-Fi.
Henry Nicholas III
Henry Nicholas III co-founded Broadcom Corporation with Samueli in 1991 and was its president and CEO through the cable modem boom, the April 1998 IPO and a string of stock-funded acquisitions in 1999 and 2000. He resigned in January 2003.
CEOs and their tenures
Amgen
- George B. Rathmann1980–1988
Chief Executive Officer
George Rathmann, a physical chemist who had run research and development at Abbott Laboratories, was named Amgen's first chief executive in 1980 and worked from a small trailer so that laboratory space could go to scientists.
Source - Gordon M. Binder1988–2000
Chief Executive Officer
Gordon Binder joined Amgen as chief financial officer in 1982 and led its June 1983 initial public offering.
Source - Kevin W. Sharer2000–2012
Chief Executive Officer
Kevin Sharer joined Amgen in 1992 as president and chief operating officer and became chairman and chief executive in 2000.
Source - Robert A. Bradway2012–present
Chairman and Chief Executive Officer
Robert Bradway became chief executive on May 23, 2012, succeeding Kevin Sharer as the fourth CEO in Amgen's history, and added the chairmanship at the start of 2013.
Source
Broadcom
- Henry Samueli1991–present
Co-Founder and Chairman of the Board
Henry Samueli co-founded Broadcom Corporation in 1991 and, as chief technical officer, led the engineering behind its cable modem, Ethernet and Wi-Fi chips. He joined the board after Avago bought Broadcom Corporation in 2016 and is chairman of Broadcom Inc.
Source - Henry Nicholas III1991–2003
Co-Founder; President and CEO of Broadcom Corporation
Henry Nicholas III ran Broadcom Corporation from its founding through its April 1998 IPO and the dot-com boom, then resigned in January 2003. Backdating and drug charges brought against him in 2008 were dismissed in December 2009 and January 2010.
Source - Scott McGregor2005–2016
President and CEO of Broadcom Corporation
Scott McGregor led Broadcom Corporation from 2005 until Avago completed its $37 billion acquisition in February 2016, a period when the company expanded in Wi-Fi, Bluetooth, set-top box and data center switch chips.
Source - Hock Tan2006–present
President and Chief Executive Officer
Hock E. Tan became CEO of Avago Technologies in March 2006 and has run the company through its acquisitions of LSI (2014), Broadcom Corporation (2016), Brocade (2017), CA Technologies (2018), Symantec's enterprise business (2019) and VMware (2023).
Source - Kirsten Spears2020–2026
Chief Financial Officer
Kirsten Spears was CFO for about six years of her 12 years at Broadcom, covering the VMware financing and the AI-driven growth of 2024 and 2025. She retired on 12 June 2026 and agreed to advise the company for nine months.
Source - Amie Thuener2026–present
Chief Financial Officer
Amie Thuener joined Broadcom as CFO on 12 June 2026 from Alphabet, where she had been vice president, corporate controller and chief accounting officer since 2018, after an earlier career at PricewaterhouseCoopers.
Source
Timeline: Amgen and Broadcom side by side
1980Amgen
Applied Molecular Genetics is incorporated
Applied Molecular Genetics (AMGen) was incorporated on April 8, 1980 in Thousand Oaks, California, as the idea of venture capitalist William K. Bowes Jr. and a group of scientific collaborators.
1983Amgen
Nasdaq listing and the erythropoietin clone
Amgen completed its initial public offering on June 17, 1983, raising nearly US$40 million under chief financial officer Gordon Binder, and formally shortened its name to Amgen.
1984Amgen
Kirin-Amgen joint venture formed
Amgen and Kirin Brewery Company of Japan formed Kirin-Amgen in 1984 as a joint venture for the worldwide commercialization of erythropoietin.
1985Amgen
G-CSF cloned, leading to Neupogen
While Fu-Kuen Lin's team worked on erythropoietin, researcher Larry Souza and his group cloned and expressed human granulocyte colony-stimulating factor in 1985.
1989Amgen
FDA approves Epogen
The FDA approved Epogen (epoetin alfa) on June 1, 1989 for anemia in patients with chronic kidney failure on dialysis. It was the first commercial recombinant human erythropoietin. Epogen's U.S.
1991Amgen
Neupogen approved, giving Amgen a second franchise
The FDA approved Neupogen (filgrastim) in February 1991. By stimulating white blood cell production it reduced the risk of infection in cancer patients with chemotherapy-induced neutropenia.
1991Amgen
Amgen wins the erythropoietin patent fight
On March 6, 1991 the U.S. Court of Appeals for the Federal Circuit upheld the Kirin-Amgen erythropoietin patent and ruled against Genetics Institute in Amgen v. Chugai Pharmaceutical and Genetics Institute.
1991Broadcom
Broadcom Corporation founded
UCLA professor Henry Samueli and his former doctoral student Henry Nicholas III found Broadcom Corporation in Los Angeles to build broadband communications chips in CMOS, starting with chips for cable modems and digital set-top boxes.
1998Broadcom
Broadcom Corporation IPO
Broadcom Corporation lists on Nasdaq in April 1998 at $24 a share, as cable operators roll out DOCSIS cable modems built on its chips.
2001Amgen
FDA approves Aranesp, the longer-acting EPO
Aranesp (darbepoetin alfa), an erythropoietin analogue with modified glycosylation and a longer half-life, was approved in 2001. Less frequent dosing than Epogen improved convenience and gave Amgen a newer, higher-priced product to migrate patients toward.
2002Amgen
US$16 billion Immunex acquisition brings Enbrel in-house
Amgen completed its acquisition of Immunex Corporation on July 16, 2002, the largest biotechnology deal to that point at about US$16 billion in stock and cash.
2005Broadcom
Avago Technologies formed
KKR and Silver Lake buy Agilent Technologies' semiconductor products group, whose roots go back to Hewlett-Packard's chip operations, for about $2.66 billion and name it Avago Technologies.
2006Broadcom
Hock Tan becomes CEO of Avago
Hock Tan becomes president and CEO of Avago in March 2006 and begins pruning its portfolio to the businesses with defensible technology.
2009Broadcom
Avago lists on Nasdaq
Avago Technologies goes public on Nasdaq in August 2009 at $15 a share, giving it stock to use in later acquisitions.
2010Amgen
Prolia and XGEVA create the bone health franchise
The FDA approved Prolia (denosumab) for postmenopausal osteoporosis in June 2010 and XGEVA, the same molecule at a higher dose, for prevention of skeletal-related events in cancer patients in November 2010.
2014Broadcom
LSI Corporation acquired
Avago completes its $6.6 billion purchase of LSI in May 2014, adding storage controllers and custom ASIC design teams.
2016Broadcom
Avago buys Broadcom Corporation
Avago completes its $37 billion acquisition of Broadcom Corporation in February 2016, takes the Broadcom name and trades as AVGO.
2017Broadcom
Brocade acquired
Broadcom completes its $5.9 billion purchase of Brocade Communications in November 2017, adding Fibre Channel storage networking switches.
2018Broadcom
Qualcomm bid blocked and move to the U.S.
President Trump blocks Broadcom's unsolicited bid for Qualcomm on national security grounds in March 2018. Broadcom completes its redomicile from Singapore to the United States that April.
2018Broadcom
CA Technologies acquired
Broadcom completes its $18.9 billion purchase of CA Technologies in November 2018, its first large software deal, creating the infrastructure software segment.
2019Amgen
US$13.4 billion purchase of Otezla from Celgene
Amgen agreed in August 2019 to buy worldwide rights to Otezla (apremilast) from Celgene for US$13.4 billion in cash, or about US$11.2 billion net of the present value of US$2.2 billion of anticipated future cash tax benefits, and closed on November 21, 2019.
2019Broadcom
Symantec enterprise security acquired
Broadcom buys Symantec's enterprise security business for $10.7 billion in November 2019, adding endpoint, web and data loss prevention software.
2020Amgen
Amgen joins the Dow Jones Industrial Average
Amgen replaced Pfizer in the Dow Jones Industrial Average on August 31, 2020, becoming one of the thirty components in the index. Inclusion recognized the scale Amgen had reached and added passive demand from Dow-tracking funds.
2022Broadcom
VMware deal announced
Broadcom agrees in May 2022 to buy VMware in a cash-and-stock deal valued at about $61 billion at announcement.
2023Amgen
US$27.8 billion Horizon Therapeutics acquisition closes
Amgen completed the acquisition of Horizon Therapeutics plc on October 6, 2023 for US$116.50 per share in cash, an equity value of about US$27.8 billion, after settling FTC litigation with a behavioral consent decree.
2023Broadcom
VMware acquisition closes
Broadcom completes the VMware acquisition on 22 November 2023 after clearances in the U.S., EU, UK and China, a deal valued at about $69 billion including assumed debt.
2024Amgen
Imdelltra becomes the first T-cell engager for small cell lung cancer
The FDA granted accelerated approval to tarlatamab, sold as Imdelltra, on May 16, 2024 for extensive stage small cell lung cancer that has progressed on or after platinum-based chemotherapy.
2024Broadcom
Stock split and $1 trillion market value
Broadcom splits its stock 10-for-1 in July 2024, sells VMware's end-user computing unit to KKR for about $4 billion, reports fiscal 2024 revenue of $51.6 billion and passes $1 trillion in market value in December 2024.
2025Amgen
VESALIUS-CV extends the Repatha case to primary prevention
In November 2025 Amgen reported Phase 3 VESALIUS-CV results in more than 12,000 patients with atherosclerosis or diabetes but no prior heart attack or stroke.
2025Broadcom
OpenAI partnership and record fiscal 2025
OpenAI and Broadcom agree in October 2025 to deploy 10 gigawatts of OpenAI-designed accelerators. Fiscal 2025 revenue rises 24% to $63.9 billion, with about $20 billion from AI chips.
2026Amgen
Medicare price setting reaches Enbrel and Otezla
Enbrel's negotiated Medicare price under the Inflation Reduction Act took effect on January 1, 2026, after it was named in the first round of ten drugs selected for negotiation.
2026Broadcom
AI chips pass half of revenue
Amie Thuener becomes CFO in June 2026. Third-quarter fiscal 2026 revenue rises 86% to $29.6 billion, and AI semiconductor revenue of $16.7 billion is 56% of the total.
Acquisitions
Amgen
- Horizon Therapeutics plc2023$27.8B
- ChemoCentryx, Inc.2022$3.7B
- Five Prime Therapeutics2021$1.9B
- Celgene Otezla Business2019$13.4B
- Onyx Pharmaceuticals, Inc.2013$10.4B
- DeCODE Genetics2012$415M
Broadcom
- VMware2023$69B
- Symantec Enterprise Security business2019$10.7B
- CA Technologies2018$18.9B
- Brocade Communications Systems2017$5.9B
- Broadcom Corporation2016$37B
- LSI Corporation2014$6.6B
Questions about Amgen vs Broadcom
Who is the CEO of Amgen Inc. and Broadcom Inc.?
Amgen Inc. is led by Robert A. Bradway and Broadcom Inc. is led by Hock Tan. Both serve as the top executive responsible for the company's strategy, operations, and financial performance.
When was Amgen Inc. founded vs Broadcom Inc.?
Amgen Inc. was founded in 1980 — 11 years before Broadcom Inc., which was founded in 1991. Amgen Inc.'s longer operating history gives it a deeper track record but also potentially more institutional inertia compared to the younger Broadcom Inc..
How many employees does Amgen Inc. have compared to Broadcom Inc.?
Amgen Inc. employs approximately 31,500 people, while Broadcom Inc. employs approximately 33,000. Broadcom Inc. has the larger workforce at 33,000 employees, compared to Amgen Inc.'s 31,500. A higher headcount does not necessarily imply greater efficiency — it often reflects differences in business model (e.g., manufacturing vs. software).
Where are Amgen Inc. and Broadcom Inc. headquartered?
Both Amgen Inc. and Broadcom Inc. are headquartered in United States, meaning they operate under the same primary regulatory and tax environment.
Who founded Amgen Inc. and Broadcom Inc.?
Amgen Inc. was founded by George B. Rathmann, William K. Bowes Jr.. Broadcom Inc. was founded by Henry Samueli, Henry Nicholas III.
Which company has a longer operating history — Amgen Inc. or Broadcom Inc.?
Amgen Inc. has been operating for approximately 46 years, making it the more established of the two companies. Broadcom Inc. has been in operation for around 35 years. A longer operating history often signals greater institutional resilience and brand recognition, though it can also mean slower adaptation to new market conditions.
Figures come from each company's filings and the sources linked beside them. Amounts reported in another currency are shown in US dollars at an approximate rate and marked with ~. Back to the Amgen vs Broadcom overview